Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-predictable routine of meetings, deadlines, and the like has, of course returned. To cope, yes, we are firing up the coffee kettle and brewing a few needed cups of stimulation. We are starting today with chocolate cherry decadence. Feel free to join us, or if you prefer, grab a bottle of water. Meanwhile, here are a few items of interest to get you going. Hope all goes well today and you conquer the world …

GlaxoSmithKline (GSK) agreed to buy Tesaro (TSRO) for $5.1 billion, gaining a class of cancer drugs called PARP inhibitors that work by blocking an enzyme that cancer cells use to repair damage in their DNA, STAT writes. PARP inhibitors are believed to be active in ovarian and prostate cancers, and are being studied in combination with immunotherapy drugs. The deal is expected to allow the big drug maker to “develop wholly owned combination therapies in multiple tumor types,” Glaxo chief executive Emma Walmsley says.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!